Notable Wednesday Option Activity: DVN, CLX, IONQ

Clorox (CLX) saw 9,768 options contracts trade (≈976,800 underlying shares), about 43.4% of its one‑month average daily volume (2.2M shares); heavy activity concentrated in the $110 call expiring Feb 20, 2026 with 3,182 contracts (~318,200 shares). IonQ (IONQ) recorded 89,726 contracts (≈9.0M shares), ≈43.4% of its one‑month average daily volume (20.7M shares), led by a $35 put expiring Mar 20, 2026 with 7,130 contracts (~713,000 shares). The flow indicates significant concentration at specific strikes/expirations that may reflect directional positioning or hedging rather than fundamental news.

Analysis

Market structure: The oversized CLX Feb-20-2026 $110 call block (~318k shares) and IONQ Mar-20-2026 $35 put block (~713k shares) are each ~43% of one-month ADV — large enough to move intraday prices and implied vol. Winners are option buyers/initiators (directional traders or hedgers) and liquidity providers; short-term beneficiaries for CLX could be stock holders if dealer hedging/supply dynamics create buy flows into the equity. For IONQ the heavy put activity signals concentrated downside protection or directional shorts that can amplify negative price moves in a low-float, high-volatility name.

Risk assessment: Tail risks include a funding/dilution event or failed technical milestone for IONQ (>=50% downside scenario) and a macro-driven consumer-spend shock for CLX (>=20% downside in staples if recession deepens). Immediate (days) risk is gamma-driven price whipsaw near strikes/expiries; short-term (weeks–months) risk is IV repricing into Feb/Mar 2026 expiries; long-term (quarters) fundamentals (CLX margins, IONQ cash runway) reassert. Hidden dependency: large block could be part of multi-legged spreads or corporate activity (buyback/activist) and not pure directional risk.

Trade implications: For CLX, prefer constrained bullish exposure (Feb20 2026 110/125 call debit spread) sized 1–3% portfolio notional to capture upside while limiting premium decay; alternatively add 1–2% long equity if IV spikes <20% above 30-day median. For IONQ, avoid naked short; buy Mar20 2026 35/25 put spreads or establish a 1–2% short position funded by out-of-the-money call sales to limit tail; consider hedging existing long stakes with these puts. Sector rotation: modest increase to defensive staples (CLX) versus reduction in speculative quantum/early-stage tech exposure over next 3–6 months.

Contrarian angles: The market may misread heavy put volume in IONQ as pure directional bearishness when it's often insurance bought by longs — if open interest rises without delta shift, downside may be priced-in and create an oversold bounce. Conversely, the CLX call block could be an activist/structured trade; if so, a follow-through buyback or dividend action is possible and current prices may understate upside. Monitor open interest, skew shifts, and dealer flow for 2–6 week signals; a gamma squeeze into strike near expiries can reverse quickly if positions are unwound.

Key Decisions for Investors

• Establish a 1.5–3.0% long position in CLX via a Feb-20-2026 110/125 call debit spread (buy 1x 110 call, sell 1x 125 call) to cap premium outlay; exit or roll by Feb 10, 2026 if spread profit >30% or IV >+40% vs 30-day median.
• For IONQ, deploy a defensive 1.0–2.0% notional protection trade: buy Mar-20-2026 35/25 put vertical (cost-limited protection). If not long equity, consider a tactical 1.0% short equity position only after confirmation of weakening price action below the $35 strike with 20% stop-loss.
• Implement a pair trade: increase staples exposure by 1–2% (long CLX) funded by a 1–2% reduction in speculative small-cap tech exposure (reduce IONQ or an equivalent ETF position) for a 3–6 month horizon to capture potential defensive re-rating.